European Heart Journal Supplements,
Journal Year:
2025,
Volume and Issue:
27(Supplement_3), P. iii60 - iii63
Published: March 1, 2025
Abstract
Transcatheter
edge-to-edge
repair
(TEER)
is
currently
indicated
in
symptomatic
patients
with
severe
functional
mitral
regurgitation
(MR)
who
are
not
eligible
for
surgery
and
have
a
high
likelihood
of
responding
to
treatment.
This
recommendation
based
on
two
randomized
trials
suggesting
that
the
benefits
TEER
may
be
limited
MR,
defined
by
an
effective
regurgitant
orifice
area
(EROA)
≥0.40
cm2,
non-excessively
remodelled
left
ventricle.
The
RESHAPE-HF2
study
recently
showed
compared
medical
therapy
alone,
treatment
MitraClip
heart
failure
less
lower
EROA
(mean
0.23
cm2),
associated
significant
reduction
hospitalizations
failure,
improvement
symptoms
quality
life,
without
clear
benefit
mortality.
However,
within
cohort
MR
enrolled
study,
alone
seem
more
selected
characteristics
higher
risk
exacerbation,
importance
careful
selection
could
from
TEER.
European Journal of Heart Failure,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 28, 2025
Abstract
Aims
While
it
is
widely
accepted
that
intravenous
(IV)
iron
improves
functional
capacity,
symptoms,
and
cardiovascular
outcomes
in
patients
with
heart
failure
(HF)
reduced
ejection
fraction
(HFrEF)
diagnosed
deficiency
(ID),
three
recently
published
outcome
trials
(AFFIRM‐AHF,
IRONMAN
HEART‐FID)
of
IV
supplementation
HF
failed
to
demonstrate
a
significant
benefit
on
their
respective
primary
endpoints.
Dosing
after
the
initial
correction
baseline
ID
–
by
design
or
as
result
trial
circumstances
was
relatively
low
(i.e.
<500
mg/year).
The
objective
FAIR‐HF2
evaluate
treatment
effect
ferric
carboxymaltose
(FCM)
compared
placebo
ambulatory
HFrEF
using
higher
dose
during
follow‐up
>1000
second
study
create
prospective
evidence
for
fulfilling
new
definition
HF,
i.e.
those
transferrin
saturation
<20%.
Methods
an
investigator‐initiated,
multicentre,
randomized,
double‐blind,
placebo‐controlled
has
recruited
1105
chronic
left
ventricular
≤45%
concomitant
ID,
defined
serum
ferritin
<100
ng/ml
100–299
Patients
were
consented
randomized
receive
either
FCM
(treatment)
saline
(placebo).
During
estimated
median
over
2
years,
underwent
repletion
maintenance
phase,
up
2000
mg,
followed
500
mg
every
4
months
unless
stop
criteria
haemoglobin
>16
mg/dl
>800
are
met
repeat
visits.
will
hypotheses:
(i)
time
first
event
death
hospitalization
(ii)
rate
total
(first
recurrent)
hospitalizations
(both
analysed
full
population),
(iii)
<20%
at
baseline.
familywise
type
I
error
across
endpoint
hypotheses
be
controlled
Hochberg
procedure
(alpha
0.05).
Conclusion
efficacy
improving
utilizing
more
aggressive
approach
towards
ensuring
prevention
transitional
targets
have
been
met.
Journal of the American College of Cardiology,
Journal Year:
2024,
Volume and Issue:
84(24), P. 2347 - 2363
Published: Aug. 31, 2024
For
patients
with
functional
mitral
regurgitation
(FMR)
and
symptomatic
heart
failure
(HF),
randomized
trials
of
transcatheter
edge-to-edge
repair
(M-TEER)
have
produced
conflicting
results.
Trends in Cardiovascular Medicine,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Feb. 1, 2025
Mitral
valve
transcatheter
edge-to-edge
repair
(M-TEER)
has
emerged
as
a
transformative
therapy
for
mitral
regurgitation
(MR),
addressing
the
unmet
needs
of
patients
unsuitable
surgery.
Landmark
trials
such
EVEREST
II,
COAPT,
and
MITRA-FR
have
established
safety
efficacy
M-TEER,
in
both
with
primary
(PMR)
secondary
MR
(SMR).
Recent
trials,
including
RESHAPE-HF2
MATTERHORN,
expanded
our
understanding
refueled
discussions
regarding
patient
selection
appropriate
treatment
indications
SMR.
These
also
contributed
to
discussion
SMR
phenotypes
most
M-TEER.
This
review
summarizes
evidence
from
pivotal
discusses
selection,
device
advancements,
potential
future
directions,
outlines
ongoing
that
may
shape
clinical
practice.
European Journal of Heart Failure,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 8, 2025
Abstract
Aims
Secondary
mitral
regurgitation
(SMR)
and
tricuspid
(TR)
are
the
most
common
valvular
heart
diseases
in
patients
with
failure
(HF).
Transcatheter
edge‐to‐edge
repair
(TEER)
devices
designed
for
treating
MR
TR
have
been
successfully
tested
randomized
controlled
trials,
but
methodological
issues
often
challenged
their
interpretation.
This
manuscript
aimed
to
provide
an
overview
of
TEER
registries
on
SMR
HF,
highlighting
key
features,
describing
clinical
characteristics
outcomes
receiving
these
devices,
exploring
available
data
limitations.
Methods
results
PubMed,
Web
Science,
EMBASE
were
searched
reporting
or
TR.
Registries
excluded
if
single‐centre
<100
patients.
Twenty‐six
(46%
prospective,
12%
ongoing),
including
a
total
cohort
18
925
patients,
retrieved
SMR,
six
(50%
retrospective,
33%
ongoing)
reported
use
1412
Limited
geographical
representativity
outside
North
America
Europe,
high
number
missing
values,
inconsistency
main
existing
evidence
Conclusion
represent
source
setting
where
it
is
difficult
conduct
trials.
However,
limitations
design,
patient
characterization,
restrain
use.
A
novel
conceptual
framework
future
prospective
registries,
as
proposed
this
document,
might
inform
current
practice,
address
relevant
questions
trial
design.
BMC Cardiovascular Disorders,
Journal Year:
2025,
Volume and Issue:
25(1)
Published: Jan. 10, 2025
The
transcatheter
edge-to-edge
repair
(TEER)
technique,
facilitated
by
the
MitraClip
device,
is
a
minimally
invasive
intervention
designed
for
high-risk
patients
with
mitral
regurgitation
(MR).
This
study
conducts
retrospective
analysis
of
death
events
associated
implantation
over
ten-year
decade,
utilizing
data
from
FDA's
Manufacturer
and
User
Facility
Device
Experience
(MAUDE)
database
to
evaluate
trends
in
safety
outcomes.
A
comprehensive
search
publicly
accessible
MAUDE
was
conducted
retrieve
reports
deaths
injuries
related
October
2013
September
2023.
Duplicate
records
unrelated
sources
were
excluded.
Cochran-Armitage
test
performed
proportion
fatal
time.
During
10-year
period
following
FDA
approval,
recorded
total
927
9,211
injury
MitraClip.
After
excluding
duplicates
irrelevant
reports,
592
cases
analyzed.
most
commonly
reported
complications
MR
(26.69%),
tissue
damage
(24.16%),
hypotension
(22.13%).
frequent
device-related
issues
incomplete
coaptation
(14.70%),
difficulty
removing
divice
(6.42%),
failure
adhere
or
bond/positioning
failure(4.90%).
Notably,
76.94%
occurred
within
one
year
implantation.
demonstrated
gradual
decline,
15.9%
2014–2015
3.5%
2020–2021
(p
<
0.0001).
indicates
decline
implantation,
which
may
be
attributed
growing
operator
experience
advancements
device
design.
Nonetheless,
persistent
focus
required
on
managing
addressing
potential
risks
further
enhance
performance
optimize
its
clinical
utility.
